Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS)

Kosuke Matsuzono, Kota Sato, Syoichiro Kono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano, Koji Abe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Objective: Alzheimer's disease (AD) is one of the most important diseases in an aging society, but the clinical effects of rivastigmine have not been fully examined in real world domestic clinics. Methods: We performed the "Okayama Rivastigmine Study (ORS)" to retrospectively analyze the clinical effects of rivastigmine (n=75) or donepezil (n=71) on AD patients with seven dementia assessment batteries at the baseline, 3, 6, and 12 months. In addition, we divided the rivastigmine group into two subgroups at the baseline: the mild behavioral and psychological symptoms of dementia (BPSD) group (Abe's BPSD score (ABS)

Original languageEnglish
Pages (from-to)757-763
Number of pages7
JournalJournal of Alzheimer's Disease
Volume48
Issue number3
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Rivastigmine
Dementia
Behavioral Symptoms
Alzheimer Disease
Psychology

Keywords

  • Affective function
  • Alzheimer's disease
  • cognitive function
  • donepezil
  • rivastigmine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS). / Matsuzono, Kosuke; Sato, Kota; Kono, Syoichiro; Hishikawa, Nozomi; Ohta, Yasuyuki; Yamashita, Toru; Deguchi, Kentaro; Nakano, Yumiko; Abe, Koji.

In: Journal of Alzheimer's Disease, Vol. 48, No. 3, 01.10.2015, p. 757-763.

Research output: Contribution to journalArticle

@article{2fd1e446f0ca41ebb56452a07235bfb3,
title = "Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS)",
abstract = "Background/Objective: Alzheimer's disease (AD) is one of the most important diseases in an aging society, but the clinical effects of rivastigmine have not been fully examined in real world domestic clinics. Methods: We performed the {"}Okayama Rivastigmine Study (ORS){"} to retrospectively analyze the clinical effects of rivastigmine (n=75) or donepezil (n=71) on AD patients with seven dementia assessment batteries at the baseline, 3, 6, and 12 months. In addition, we divided the rivastigmine group into two subgroups at the baseline: the mild behavioral and psychological symptoms of dementia (BPSD) group (Abe's BPSD score (ABS)",
keywords = "Affective function, Alzheimer's disease, cognitive function, donepezil, rivastigmine",
author = "Kosuke Matsuzono and Kota Sato and Syoichiro Kono and Nozomi Hishikawa and Yasuyuki Ohta and Toru Yamashita and Kentaro Deguchi and Yumiko Nakano and Koji Abe",
year = "2015",
month = "10",
day = "1",
doi = "10.3233/JAD-150518",
language = "English",
volume = "48",
pages = "757--763",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS)

AU - Matsuzono, Kosuke

AU - Sato, Kota

AU - Kono, Syoichiro

AU - Hishikawa, Nozomi

AU - Ohta, Yasuyuki

AU - Yamashita, Toru

AU - Deguchi, Kentaro

AU - Nakano, Yumiko

AU - Abe, Koji

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background/Objective: Alzheimer's disease (AD) is one of the most important diseases in an aging society, but the clinical effects of rivastigmine have not been fully examined in real world domestic clinics. Methods: We performed the "Okayama Rivastigmine Study (ORS)" to retrospectively analyze the clinical effects of rivastigmine (n=75) or donepezil (n=71) on AD patients with seven dementia assessment batteries at the baseline, 3, 6, and 12 months. In addition, we divided the rivastigmine group into two subgroups at the baseline: the mild behavioral and psychological symptoms of dementia (BPSD) group (Abe's BPSD score (ABS)

AB - Background/Objective: Alzheimer's disease (AD) is one of the most important diseases in an aging society, but the clinical effects of rivastigmine have not been fully examined in real world domestic clinics. Methods: We performed the "Okayama Rivastigmine Study (ORS)" to retrospectively analyze the clinical effects of rivastigmine (n=75) or donepezil (n=71) on AD patients with seven dementia assessment batteries at the baseline, 3, 6, and 12 months. In addition, we divided the rivastigmine group into two subgroups at the baseline: the mild behavioral and psychological symptoms of dementia (BPSD) group (Abe's BPSD score (ABS)

KW - Affective function

KW - Alzheimer's disease

KW - cognitive function

KW - donepezil

KW - rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=84943788619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943788619&partnerID=8YFLogxK

U2 - 10.3233/JAD-150518

DO - 10.3233/JAD-150518

M3 - Article

C2 - 26402119

AN - SCOPUS:84943788619

VL - 48

SP - 757

EP - 763

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -